Plenaxis
Evidence Grade C — Moderate human evidence. 55 published studies, 42 human. 3 registered clinical trials.
Abarelix (previously sold as Plenaxis) was the first GnRH antagonist approved for prostate cancer — but it was withdrawn from the US market in 2005 after just two years due to serious allergic reactions. Despite its clinical failure, it was historically important as proof that GnRH antagonists could treat prostate cancer without the testosterone surge that limits older treatments.
55 published studies: 42 human, 3 animal, 6 in-vitro, 19 reviews
Abarelix was marketed as Plenaxis (approved November 2003) with a highly restrictive indication — it was only approved for symptomatic advanced prostate cancer where no other treatment options existed, and required a mandatory prescriber registry and monitoring programme. It was withdrawn from the US market in May 2005.
The withdrawal was driven by reports of immediate-onset systemic allergic reactions, combined with the restricted indication limiting commercial uptake. Despite its clinical failure, abarelix was historically important as proof that GnRH antagonists could effectively treat prostate cancer without the testosterone flare. This directly enabled the development of degarelix (approved 2008) and relugolix (approved 2020), both of which addressed the safety concerns that ended abarelix's commercial life.
Abarelix works by directly blocking the GnRH receptor in the pituitary gland, immediately suppressing testosterone production without the initial hormone surge caused by GnRH agonists. While this mechanism was clinically effective, abarelix caused a higher rate of serious allergic reactions (including immediate-onset systemic reactions) compared to later GnRH antagonists. Research suggests this was related to the compound's tendency to trigger histamine release — a problem that was specifically designed out of the next-generation antagonist degarelix.
Research suggests abarelix effectively suppressed testosterone but caused immediate-onset systemic allergic reactions at rates that were unacceptable for a non-life-threatening indication. It was approved only under highly restrictive conditions — limited to symptomatic advanced disease where no alternatives existed, with a mandatory prescriber registry and monitoring programme. Abarelix's withdrawal directly enabled the development of safer successors: degarelix (approved 2008) addressed the allergic reaction problem, and relugolix (approved 2020) offered the first oral option. The compound serves as a cautionary example about immunogenicity in peptide drug development. No current research programmes exist.
Diagnosis of Pelvic Endometriosis in MRI
The Plenaxis® Experience Study
Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Histrelin is available as Supprelin LA for central precocious puberty (approved 2007). The Vantas implant for prostate cancer was approved in 2004 but discontinued in 2021. The implant requires a minor surgical procedure for insertion and removal/replacement each year. Supprelin LA's main clinical advantage is its 12-month duration — the longest of any GnRH agonist — which is particularly valuable in paediatric patients where treatment compliance over years is important. Clinical studies demonstrated effective suppression of puberty markers in over 97% of patients. The implant has also seen significant off-label use in gender-affirming care as a puberty blocker, where its annual dosing schedule offers practical benefits for adolescent patients and their families.
Goserelin is marketed as Zoladex by AstraZeneca, available as 3.6 mg monthly and 10.8 mg three-monthly subcutaneous implants. First approved in 1989, it is used in advanced prostate cancer, premenopausal breast cancer, endometriosis, and for thinning the uterine lining before surgical procedures. Goserelin achieves castrate-level testosterone suppression (below 50 ng/dL) within two to four weeks. Its unique implant delivery system means there is no liquid injection, reconstitution, or refrigeration required — a practical advantage in some clinical settings. Like all GnRH agonists, it causes an initial hormone flare before suppression takes effect. Goserelin holds an important niche in breast cancer treatment, where it is used to suppress ovarian function in premenopausal women with hormone-receptor-positive disease, often in combination with aromatase inhibitors.
Nafarelin is marketed as Synarel (approved 1990) for endometriosis and central precocious puberty. It requires administration as one spray in each nostril twice daily — a higher frequency than injectable alternatives but avoids needles entirely, which can be a significant advantage for some patients, particularly children. Clinical trials showed symptom improvement in 75–92% of endometriosis patients. However, absorption can be affected by nasal congestion or concurrent use of nasal decongestants, which can be a practical limitation. As with all GnRH agonists, prolonged use leads to bone density loss, and treatment for endometriosis is typically limited to six months. Nafarelin occupies a niche for patients who prefer non-injectable hormone suppression, though it has become less commonly prescribed as longer-acting depot injections and oral alternatives have become available.
